Headlines

Allergan to Cut 1,000+ Jobs

Published

6 years ago

January 4, 2018

It will also slash 400 unfilled positions.

Allergan plc plans to cut more than 1,000 jobs, affecting employees “in commercial and other functions.”

The company will also cut 400 currently open positions, according to a filing it made with the U.S. Securities and Exchange Commission.

Allergan stated in November that it would undertake a cost cutting and restructuring program to help it meet its 2018 financial goals. The actions come “in response to the anticipated loss of exclusivity of several key revenue-generating products in 2018.”

Reuters notes that the job eliminations come as Allergan “works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.”

The company expects to incur restructuring costs of about $125 million, mainly due to severance. That amount doesn’t include additional charges related to potential building closures, contract terminations and other items.

Expense savings from the restructuring are expected to be in the range of $300 to $400 million as compared to the fiscal year 2017, Allergan stated.

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width³ according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion⁴ and seamless transitions from near to far.

For more information, visit here.